Hypothesis

Rapamycin extends lifespan not by repairing damage but by imposing a metabolic state that mimics ancestral scarcity. A key, yet untested, consequence of systemic mTORC1 inhibition is the attenuation of the bone‑derived hormone osteocalcin (OCN) and its downstream activation of mTORC1 in muscle and osteoblasts. We hypothesize that the longevity benefit of rapamycin depends, in part, on suppressing the OCN‑mTORC1 anabolic axis, thereby shifting resources from growth and tissue repair to stress‑resistance programs. This trade‑off extends survival at the expense of musculoskeletal health, producing a phenotype of longevity with frailty.

Mechanistic rationale

• Osteocalcin, when uncarboxylated, binds GPRC6A receptors on myocytes and osteoblasts, stimulating mTORC1‑dependent protein synthesis and bone formation [2, 3].
• Rapamycin inhibition of mTORC1 blunts this signal, reducing anabolic drive while concurrently activating autophagy and suppressing SASP translation [1, 4].
• In aging, circulating OCN already declines; rapamycin‑induced further suppression creates a hormetic ‘scarcity’ signal that favors survival pathways over anabolic ones.

Testable predictions

1. Chronic rapamycin treatment will lower serum uncarboxylated OCN and decrease p‑S6K (mTORC1 read‑out) in muscle and bone.
2. Exogenous administration of uncarboxylated OCN during rapamycin treatment will restore mTORC1 activity in these tissues, attenuate autophagy induction, and shorten lifespan without increasing damage markers.
3. Mice receiving rapamycin plus OCN will retain the rapamycin‑induced reduction in inflammatory SASP but show improved bone mineral density, muscle mass, and grip strength compared with rapamycin‑alone mice.
4. Conversely, genetic deletion of GPRC6A will phenocopy rapamycin’s musculoskeletal side‑effects and not further extend lifespan when combined with rapamycin, indicating epistatic relationship.

Experimental design

• Use C57BL/6 mice, start treatment at 12 mo of age.
• Groups: (i) control, (ii) rapamycin (14 ppm diet), (iii) rapamycin + uncarboxylated OCN (daily intraperitoneal injection), (iv) OCN alone, (v) GPRC6A‑KO + rapamycin.
• Monitor survival, frailty index, μCT bone metrics, muscle fiber cross‑sectional area, serum OCN, p‑S6K, LC3‑II/I, and SASP cytokines (IL‑6, CXCL1).

Falsifiability If OCN supplementation does not diminish rapamycin‑mediated lifespan extension (i.e., survival curves remain indistinguishable), the hypothesis that OCN‑mTORC1 suppression contributes to longevity is falsified. Likewise, if OCN rescue fails to improve musculoskeletal readouts despite restoring mTORC1 signaling, the proposed mechanistic link would be refuted.

Implications This hypothesis reframes rapamycin as a hormetic mimetic of scarcity that deliberately dampens an endocrine‑driven growth program. It suggests that intermittent dosing or targeted OCN supplementation could uncouple lifespan extension from frailty, offering a refined strategy for geroprotective interventions.